Quick Answer
Trevi Therapeutics, Inc. reported Stockholders Equity of $183.24 million for fiscal year 2025.
Trevi Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $183.24M | +83.9% |
| 2024 | $99.64M | +20.7% |
| 2023 | $82.55M | -23.2% |
| 2022 | $107.46M | +529.3% |
| 2021 | $17.07M | -37.4% |
| 2020 | $27.28M | -50.0% |
| 2019 | $54.55M | +149.8% |
| 2018 | -$109.49M | -29.7% |
| 2017 | -$84.43M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $189.79M | +221.8% | -4.4% |
| June 30, 2025 | $198.49M | +200.0% | +99.6% |
| March 31, 2025 | $99.46M | +37.5% | -0.2% |
| December 31, 2024 | $99.64M | +20.7% | +69.0% |
| September 30, 2024 | $58.97M | -34.2% | -10.9% |
| June 30, 2024 | $66.17M | -30.4% | -8.5% |
| March 31, 2024 | $72.33M | -28.9% | -12.4% |
| December 31, 2023 | $82.55M | -23.2% | -7.9% |
- Trevi Therapeutics, Inc. showed an increase of +83.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Trevi Therapeutics, Inc.’s stockholders equity has grown by 317.0% (from -$84.43 million to $183.24 million).
- The most recent figure is from Trevi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: